CLINICAL_TRIALS trial_result · 2017-03-06

Clinical Trial Update: Addition of UT-15C SR to Pulmonary Arterial Hypertension Patients Currently Receiving Tyvaso® [Phase 2]

Phase 2 trial update evaluating UT-15C SR added to Tyvaso in patients with pulmonary arterial hypertension; study completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: United Therapeutics | Conditions: Pulmonary Arterial Hypertension | Phase 2 | Status: COMPLETED | Results posted: 2017-03-06